Abstract |
Pixantrone (BBR-2778) is a novel mitoxantrone-like drug, which lacks the 5,8-dihyroxy substitution groups thought to be responsible for the cardiac toxicity associated with mitoxantrone. In Phase I/II single-agent pixantrone clinical trials, neutropenia was the dose-limiting toxicity and the maximum tolerated dose was 150 mg/m(2)/week for 3 weeks every 4 weeks. In relapsed aggressive non-Hodgkin's lymphomas, weekly single-agent pixantrone 85 mg/m(2) for 3 weeks every 4 weeks was associated with a 27% overall response and a 15% complete response. When intensively pretreated patients with relapsed aggressive non-Hodgkin's lymphoma were treated with a cyclophosphamide, pixantrone, vincristine and prednisolone regimen ( pixantrone substituted for doxorubicin in standard regimen [ cyclophosphamide, doxorubicin, vincristine and prednisolone regimen (CHOP)]), the overall response was 74% and complete response 57%. In the BBR-2778, methylprednisolone, cisplatin and cytosine arabinoside (BSHAP) regimen, 58% overall response and 37% complete response were achieved. A number of randomised studies of pixantrone (BBR-2778) in patients with relapsed indolent or aggressive lymphomas are ongoing.
|
Authors | Loaie M El-Helw, Barry W Hancock |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 16
Issue 10
Pg. 1683-91
(Oct 2007)
ISSN: 1744-7658 [Electronic] England |
PMID | 17922631
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Isoquinolines
- Topoisomerase II Inhibitors
- pixantrone
|
Topics |
- Animals
- Antineoplastic Agents
(adverse effects, pharmacokinetics, therapeutic use)
- Clinical Trials as Topic
- Humans
- Isoquinolines
(adverse effects, pharmacokinetics, therapeutic use)
- Lymphoma, Non-Hodgkin
(blood, drug therapy)
- Neutropenia
(chemically induced)
- Thrombocytopenia
(chemically induced)
- Topoisomerase II Inhibitors
|